# US 2008/0076735 A1 · Cytoskeletal active compounds, composition and use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0076735 A1
- Document ID: US20080076735A1
- Status: Published application
- Kind: A1
- Application number: 11/950,327
- Filed: 2007-12-04
- Published: 2008-03-27
- Earliest claimed: 2005-03-25
- Assignees: Inspire Pharmaceuticals, Inc.
- Inventors: John Lampe; Robert Plourde; Jin She; Jason Vittitow; Paul Watson; Michael Crimmins; David Slade
- Web page: https://patentgrep.com/patent/US20080076735A1

## CPC

- C07D 491/08: Bridged systems
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- C07D 277/06: with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 277/14: Oxygen atoms
- C07D 277/16: Sulfur atoms
- C07D 277/34: Oxygen atoms
- C07D 277/56: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 493/08: Bridged systems
- C07D 497/18: Bridged systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with actin polymerization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or II, wherein said amount is effective to influence the cytoskeleton, for example by inhibiting actin polymerization.

## Claims

### Claim 1

A compound of Formula I, or pharmaceutically-acceptable salts, tautomers, solvates, or hydrates thereof:
wherein:
X1=S;
Y1=NR6;
Y2=NR7;
Z1=O or absent;
Q1 and Q2 are independently O or S;
A1 and A2 are independently hydrogen, halo, alkyl, or alkoxy, optionally substituted;
n=1;
R1-R8 are independently H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, or heterocycle, optionally substituted;
with a first proviso that when Z1=S or O; R2 is not H;
with a second proviso that when n is 1, X1 is S, Y1 is NR6, Y2 is O, Z, is absent, Q1 and Q2 are O, and if R2 is selected from one of the following groups:
methyl,
then R1 is not 3-monomethyl-substituted alkyl, or R1 is not:
where the bond marked with an arrow denotes the point of attachment of the group R1 to the rest of the molecule.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein:
Q1 and Q2 are 0; and
R3-R8 are independently H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, or cycloalkylalkyl.

### Claim 3 (depends on 1)

The compound according to claim 1,
provided that when R1 is optionally substituted alkyl or alkenyl and begins with CH2CH2 from the point of attachment to the pyran ring, then R1 is:
where the bond marked with an arrow denotes the point of attachment of the group R1 to the rest of the molecule,
wherein R9-R10 are independently H, halo, alkyl, or alkenyl, optionally substituted, and
R11 is H, halo, alkyl, alkenyl, or —W—R12, optionally substituted, where W=O, S, SO, SO2, NH, or N-alkyl, and
R12 is H, alkyl, or alkenyl,
provided that if R9 is H and R10 is methyl, then R11 is H, halo, or —W—R12.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein A1 and A2 are both hydrogen, and the ring containing X1 is fully saturated.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein said compound is Compound 1a, which is (Z)-N-((2R,4R,6R)-2-hydroxy-2-((R)-2-oxothiazolidin-4-yl)-6-(pent-4-enyl)-tetrahydro-2H-pyran-4-yl)-3-methylhepta-2,6-dienamide.

### Claim 6

A compound of Formula II, or pharmaceutically-acceptable salts, tautomers, solvates, or hydrates thereof:
wherein:
Ra is an alkylene chain, from 4 to 15 atoms in length, wherein the carbon atoms of the alkylene chain are optionally replaced by from 1 to 30, S, or N atoms, wherein the alkylene chain optionally contains from 1 to 4 unsaturations, 1 to 2 cycloalkyl, 1 to 2 aryl, 1 to 2 heteroaryl, or 1 to 2 heterocycle rings, and is optionally substituted;
X1=S;
Y1=NR6;
Y2=NR7;
Z1=O or absent;
Q1 and Q2 are independently O or S;
A1 and A2 are independently hydrogen, halo, alkyl, or alkoxy, optionally substituted;
n=1;
R3-R8 are independently H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, or heterocycle, optionally substituted;
with a proviso that when Q1 and Q2 are O, then either Ra is not 3-monomethyl-substituted, as counted from the point of attachment distal to Z1; or Ra is not:
where in these structures the right-most bond marked with an arrow indicates the point of attachment of Ra to Z1, and the left-most bond marked with an arrow indicates the point of attachment of Ra to the pyran ring of Formula II.

### Claim 7 (depends on 6)

The compound according to claim 6, wherein said Ra is an alkylene chain, from 6 to 13 atoms in length, wherein a carbon atom of the alkylene chain is optionally replaced by 1 O, S, or N atom, wherein the alkylene chain optionally contains from 1 to 3 unsaturations, and is optionally substituted.

### Claim 8 (depends on 7)

The compound according to claim 7, wherein said Ra is an alkylene chain, from 8 to 11 atoms in length, wherein the alkylene chain optionally contains from 1 to 3 unsaturations, and is optionally substituted.

### Claim 9 (depends on 6)

The compound according to claim 6, wherein
Ra is an alkylene chain, from 6 to 13 atoms in length, wherein a carbon atom of the alkylene chain is optionally replaced by 1 O, S, or N atom, wherein the alkylene chain optionally contains from 1 to 3 unsaturations, and is optionally substituted;
Q1 and Q2 are O.

### Claim 10 (depends on 9)

The compound according to claim 9, wherein
Ra is an alkylene chain, from 8 to 11 atoms in length, wherein the alkylene chain optionally contains from 1 to 3 unsaturations, and is optionally substituted;
Y1=NH.

### Claim 11 (depends on 6)

The compound according to claim 6, wherein A1 and A2 are both hydrogen, and the ring containing X1 is fully saturated.

### Claim 12 (depends on 6)

The compound according to claim 6, wherein
Ra is:
(CH2)m1—(CR9R10)—(CH2)m2—V—(CH2)m3—V2
wherein:
m1, m2, and m3 are independently 0-5 inclusively, and m1+m2+m3 is between 2 and 14 inclusively;
R9 and R10 are independently H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, aryl, arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heterocycle, or —W—R12, optionally substituted;
W=O, S, SO, SO2, NH, N-alkyl, N-cycloalkyl, N-aryl, or N-heteroaryl;
R12 is H, alkyl, alkenyl, cycloalkyl, aryl, or heteroaryl;
V1 is NR13, O, S, SO, SO2, cis —C(R13)═C(R14)—, trans —C(R13)═C(R14)—, —C-(triple bond)-C—, —OC(═O)—, —C(═O)O—, —N(R13)C(═O)—, —C(═O)N(R13)—, —N(R13)C(═O)O—, —OC(═O)N(R13)—, —N(R13)SO2—, —SO2N(R13)—, —N(R13)C(═O)N(R14)—, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycle, or absent;
V2 is NR13, O, cis —C(R13)═C(R14)—, trans —C(R13)═C(R14)—, —C-(triple bond)-C—, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycle, or absent;
R13 and R14 are independently H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, aryl, arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, or heterocycle, optionally substituted;
with a proviso that when m1 is 2, m2 is 0, m3 is 2, V1 is cis —CH═CH—, V2 is —C(Me)═CH—, R9 is H, and R10 is alkyl,
then R10 is a C2-C10 alkyl.

### Claim 13 (depends on 12)

The compound according to claim 12, wherein
R9 and R10 are H, halo, alkyl, alkenyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, aryl, or arylalkyl, optionally substituted;
V1 is O, S, cis —C(R13)═C(R14)—, trans —C(R13)═C(R14)—, cycloalkyl, aryl, or absent; and
V2 is cis —C(R13)═C(R14)—, trans —C(R13)═C(R14)—, cycloalkenyl, or aryl.

### Claim 14 (depends on 6)

The compound according to claim 6, wherein
Ra is an alkylene chain, from 4 to 15 atoms in length, wherein the alkylene chain optionally contains from 1 to 4 unsaturations, 1 to 2 cycloalkyl, 1 to 2 aryl, 1 to 2 heteroaryl, or 1 to 2 heterocycle rings, and is optionally substituted.

### Claim 15 (depends on 6)

The compound according to claim 6, wherein said compound is Compound 8c, which is (1R,4Z,8Z,13R,15R)-15-hydroxy-5-methyl-15-((R)-2-oxothiazolidin-4-yl)-14-oxa-2-aza-bicyclo[11.3.1]heptadeca-4,8-dien-3-one; or Compound 8d, which is (1R,13R,15R,Z)-15-hydroxy-15-((R)-2-oxothiazolidin-4-yl)-4,14-dioxa-2-aza-bicyclo[11.3.1]heptadec-8-en-3-one.

### Claim 16 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound according to claim 1.

### Claim 17 (depends on 6)

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound according to claim 6.

### Claim 18 (depends on 1)

A method for reducing intraocular pressure, comprising the step of administering to a subject in need thereof a compound according to claim 1, in an amount effective to alter actin cytoskeleton.

### Claim 19 (depends on 18)

The method according to claim 18, wherein said compound is locally administered to the eye in the form of an ophthalmic formulation.

### Claim 20 (depends on 6)

A method for reducing intraocular pressure, comprising the step of administering to a subject in need thereof a compound according to claim 6, in an amount effective to alter actin cytoskeleton.

### Claim 21 (depends on 20)

The method according to claim 20, wherein said compound is locally administered to the eye in the form of an ophthalmic formulation.
